statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bristol-Myers Squibb Unveils Q2 2024 Financial Strategies

Bristol-Myers Squibb (BMY) just unveiled an update. Bristol Myers Squibb has made a significant announcement available on their website, detailing...

Bristol Myers Squibb Reports Second Quarter Financial Results for 2024

Bristol Myers Squibb (NYSE: BMY) today reports results for the second quarter of 2024. Our second quarter results reflect progress against our strategy to position BMS for long-term, sustainable...

Bristol-Myers Squibb, Deckers Outdoor And 3 Stocks To Watch Heading Into Friday

Key Events This Week: Core PCE, GDP, And Lots Of Earnings

Key Events This Week: Core PCE, GDP, And Lots Of Earnings

 As we head into another week full of unknowns, DB's Jim Reid notes this morning that one question that we don't need to ask...

Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma

Bristol Myers Squibb (NYSE: BMY) today announced that the European Medicines Agency (EMA) validated its Type II variation application for Opdivo (nivolumab) plus Yervoy (ipilimumab) as a potential...

What the Options Market Tells Us About Bristol-Myers Squibb

Bristol-Myers Squibb Unusual Options Activity For July 15

Spotlight on Bristol-Myers Squibb: Analyzing the Surge in Options Activity

How Is The Market Feeling About Bristol-Myers Squibb?

Bristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation Day

Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in Virtual Targeted Protein Degradation Day hosted by UBS. Robert Plenge, M.D., Ph.D., Executive Vice President...

Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases in patients with limited treatment options.   There are hundreds of clinical trials at major medical centers evaluating compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma (MM), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), pancreatic cancer, non-small lung cancer and melanoma.   In addition, several compounds are being evaluated as therapies for serious inflammatory diseases such as psoriasis and psoriatic arthritis.

Celgene Corp.

Celgene Corporation

52-Wk High	$0.00
52-Wk Low	$0.00

CELG Celgene Corporation

About

Feed

News

Fundamentals